AbbVie Inc.
ABBV- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001551152
In the last 90 days, AbbVie Inc. insiders filed 0 open-market purchases and 1 sale; 4,239 institutions reported holding it in 13F filings for Q2 2026, worth $335.4B in total; superinvestors Gardner Russo & Quinn and Harris Associates (Oakmark) hold it.
Q2 2023 vs. Q1 2023
How the institutions holding AbbVie Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 3,147 | 30 | 3,083 | −34 |
| Shares | 1.23B | 703.6K | 1.23B | −8.54M (−0.7%) |
| Value | $196.7B | $111.7M | $165.0B | −$31.6B (−16.1%) |
30 institutions that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (150)
Institutions that held AbbVie Inc. at the end of Q2 2023 but not at the end of Q1 2023.
Showing the largest 100 of 150 by value.
Sold out (184)
Institutions that held AbbVie Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
Showing the largest 100 of 184 by value.
Not filed for Q2 2023 yet (30)
Institutions that held AbbVie Inc. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.